Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Avian Influenza
Carrington comments on bird flu pandemic, provides update on DelSite vaccine
February 14th, 2007
In view of a recent article in the January 16, 2007 Wall Street Journal about a "Permanent Threat" regarding the risk of an H5N1 (bird flu) pandemic and recent incidence of human cases in Vietnam and China, Carrington Laboratories, Inc., (CARN) issued a status report on DelSite Biotechnologies, Inc.'s influenza vaccine development. DelSite, a wholly-owned subsidiary of Carrington, has been developing a platform for the development of a vaccine for an H5N1 flu pandemic with funding from the National Institute of Allergy and Infectious Disease, Department of Human Health Services (NIAID, DHHS). GelVac is the platform for nasal powder delivery of preservative-free...
Source: Medical Patent Law Weekly (2007-02-14)
|
